Mavacamten outcomes and real-world patient and physician experiences for obstructive HCM in the US

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project collects real-world clinical data and experience from adults with obstructive hypertrophic cardiomyopathy who were prescribed mavacamten in US community-based settings. Phase I uses a retrospective chart review of patients prescribed mavacamten between April 28, 2022 and December 31, 2024 who were not enrolled in interventional cardiac myosin inhibitor trials. Phase II invites eligible Phase I patients to complete an online survey if they can read English and have access to a computer or smartphone. Data sources include medical records and patient/physician questionnaires to characterize treatment patterns, clinical outcomes, and experiences with mavacamten.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Phase I: retrospective chart review

For inclusion in the study, participants must meet ALL of the following criteria:

* Are an adult aged 18 or over at baseline
* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
* Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
* Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
* Are not enrolled in any interventional clinical trial at study baseline

Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey

Exclusion Criteria:

• None with the proviso that all inclusion criteria are met.

Where it's running

• Adelphi Real World
  Bollington, Macclesfield, United Kingdom Recruiting

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mavacamten treatment for obstructive hypertrophic cardiomyopathy in Japan

  This project will try mavacamten in patients in Japan with obstructive hypertrophic cardiomyopathy to see if it works well and is safe during routine care.

  Recruiting Bristol-Myers Squibb · Tokyo · NCT07383025

• Ademetionine treatment for obstructive hypertrophic cardiomyopathy

  This study will test whether taking ademetionine can improve exercise capacity, symptoms, heart structure and quality of life in adults with obstructive hypertrophic cardiomyopathy.

  Recruiting at 2 sites Phase 2 China National Center for Cardiovascular Diseases · Beijing and 2 other locations · NCT07367724

• Assessing health changes in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten

  This study is testing how well the medication mavacamten helps adults with obstructive hypertrophic cardiomyopathy feel and do better in their everyday lives.

  Recruiting Bristol-Myers Squibb · Boston, Massachusetts · NCT06551129

• Assessing the safety of mavacamten in Korean patients with obstructive hypertrophic cardiomyopathy

  This study is testing how safe the medication mavacamten is for adults in Korea who have symptoms of obstructive hypertrophic cardiomyopathy.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06146660

• Effect of mavacamten on heart blood flow in obstructive hypertrophic cardiomyopathy

  This study is testing if the medication mavacamten can improve blood flow in the hearts of people with obstructive hypertrophic cardiomyopathy after a year of treatment.

  Recruiting University of Virginia · Charlottesville, Virginia · NCT06023186

• Registry to assess patient characteristics and outcomes in obstructive hypertrophic cardiomyopathy

  This study is trying to learn more about how people with obstructive hypertrophic cardiomyopathy are treated and what their experiences are, especially for those using the medication mavacamten.

  Recruiting at 76 sites Bristol-Myers Squibb · Anchorage, Alaska and 100 other locations · NCT05489705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.